Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 1, 2026, 1:46 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 59 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Obesity pharmacotherapy Clear all
Recruiting Phase 1Phase 2 Interventional

Probiotics and Gut Health

NCT03418857
View directory record Official record
Conditions
Metabolic Syndrome
Interventions
Yogurt smoothie with BB-12, Yogurt smoothie
Drug
Lead sponsor
Penn State University
Other
Eligibility
55 Years to 75 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2022
U.S. locations
1
States / cities
University Park, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Dec 13, 2021 · Synced Sep 1, 2026, 1:46 PM EDT
Not yet recruiting Not applicable Interventional

Continuous Wearable Biometric Monitoring in Adults Undergoing Obesity Treatment (SMART-BMI)

NCT07736729
View directory record Official record
Conditions
Obesity
Interventions
Biometric-informed care, Control Arm: Standard Care
Behavioral
Lead sponsor
Jeff Reeves
Other
Eligibility
18 Years to 64 Years
Enrollment
260 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2031
U.S. locations
1
States / cities
San Diego, California
Source: ClinicalTrials.gov public record
Updated Jul 29, 2026 · Synced Sep 1, 2026, 1:46 PM EDT
Completed Phase 3 Interventional Results available

A Study of the Safety and Efficacy of Two Doses of Naltrexone SR/Bupropion SR and Placebo in Overweight and Obese Subjects

NCT00532779
View directory record Official record
Conditions
Obesity, Overweight
Interventions
Naltrexone SR 16 mg/Bupropion SR 360 mg /day, Naltrexone SR 32 mg/Bupropion SR 360 mg /day, Placebo, Ancillary therapy
Drug · Behavioral
Lead sponsor
Orexigen Therapeutics, Inc
Industry
Eligibility
18 Years to 65 Years
Enrollment
1,742 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
34
States / cities
Birmingham, Alabama • Fairhope, Alabama • Chandler, Arizona + 28 more
Source: ClinicalTrials.gov public record
Updated Nov 20, 2014 · Synced Sep 1, 2026, 1:46 PM EDT
Completed Phase 4 Interventional Results available

A Toolbox Approach to Obesity Treatment in Primary Care

NCT01922934
View directory record Official record
Conditions
Obesity
Interventions
Commercial weight loss program, Colorado Weigh, Meal replacements, Obesity pharmacotherapy, Recreation center passes
Behavioral · Dietary Supplement · Drug
Lead sponsor
Denver Health and Hospital Authority
Other
Eligibility
18 Years to 80 Years
Enrollment
4,730 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
1
States / cities
Denver, Colorado
Source: ClinicalTrials.gov public record
Updated Aug 17, 2017 · Synced Sep 1, 2026, 1:46 PM EDT
Not yet recruiting Phase 3 Interventional

Brain Plasticity and GLP-1 Receptor Agonist Treatment for Obesity

NCT07021937
View directory record Official record
Conditions
Obesity/Therapy
Interventions
Semaglutide 1.7mg subcutaneous, Placebo
Drug
Lead sponsor
University of Colorado, Denver
Other
Eligibility
12 Years to 45 Years
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2031
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated Jul 1, 2026 · Synced Sep 1, 2026, 1:46 PM EDT
Recruiting Not applicable Interventional

Clinical Research Evaluating Smoking Cessation With E-Cigarettes and Nicotine Therapy

NCT06948058
View directory record Official record
Conditions
Smoking Cessation, Obesity and Obesity-related Medical Conditions
Interventions
Electronic Cigarettes (EC), Nicotine replacement therapy (NRT)
Other
Lead sponsor
Brown University
Other
Eligibility
21 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
Providence, Rhode Island
Source: ClinicalTrials.gov public record
Updated May 17, 2026 · Synced Sep 1, 2026, 1:46 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Enhancing Weight Loss Maintenance With GLP-1RA (BYDUREON™) in Adolescents With Severe Obesity

NCT02496611
View directory record Official record
Conditions
Severe Obesity
Interventions
Weight loss with pharmacotherapy, Weight loss without pharmacotherapy
Drug
Lead sponsor
University of Minnesota
Other
Eligibility
12 Years to 17 Years
Enrollment
100 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2020
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Jan 2, 2022 · Synced Sep 1, 2026, 1:46 PM EDT
Withdrawn No phase listed Observational Accepts healthy volunteers

Epigenetics of TNBC in Overweight and Obese Hispanic & Non-Hispanic White Women

NCT04291950
View directory record Official record
Conditions
Triple Negative Breast Cancer
Interventions
Needle core biopsy
Procedure
Lead sponsor
University of Arizona
Other
Eligibility
18 Years and older · Female only
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2025
U.S. locations
1
States / cities
Tucson, Arizona
Source: ClinicalTrials.gov public record
Updated Dec 19, 2022 · Synced Sep 1, 2026, 1:46 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Point-of-Care Testing (POCT) Detection and Management of Metabolic Syndrome in Patients With Mental Illness

NCT02029989
View directory record Official record
Conditions
Hyperlipidemia, Diabetes, Hypertension
Interventions
Glucose and lipids, Glycosylated Hemoglobin A1c, Blood Pressure and Heart Rate, Body mass index, Waist and Hip circumference, Comprehensive Medication Management
Device · Behavioral
Lead sponsor
University of Minnesota
Other
Eligibility
18 Years to 64 Years
Enrollment
121 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2012
U.S. locations
1
States / cities
Duluth, Minnesota
Source: ClinicalTrials.gov public record
Updated Apr 3, 2024 · Synced Sep 1, 2026, 1:46 PM EDT
Withdrawn Phase 2 Interventional Accepts healthy volunteers

Phentermine/Topiramate as Preventive Pharmacotherapy for Obesity

NCT05834062
View directory record Official record
Conditions
Obesity, Adolescent
Interventions
Qsymia and lifestyle management therapy, Placebo and lifestyle management therapy
Drug · Behavioral
Lead sponsor
University of Minnesota
Other
Eligibility
16 Years to 22 Years
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2027
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Oct 25, 2023 · Synced Sep 1, 2026, 1:46 PM EDT
Completed Phase 2 Interventional Results available

Daily Liraglutide for Nicotine Dependence

NCT03712098
View directory record Official record
Conditions
Smoking Cessation, Weight, Body
Interventions
Liraglutide, Placebo, Smoking Cessation Counseling
Drug · Behavioral
Lead sponsor
Rebecca Ashare
Other
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2022
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Sep 20, 2023 · Synced Sep 1, 2026, 1:46 PM EDT
Recruiting Phase 4 Interventional

Optimizing Portal Hypertension With TIPS and Interval Metabolic Surgery for Advanced Liver Disease

NCT07058155
View directory record Official record
Conditions
Liver Cirrhoses, Portal Hypertension Related to Cirrhosis, Severe Obesity, TIPS
Interventions
Transjugular Intrahepatic Portosystemic Shunt (TIPS), Sleeve Gastrectomy, Anti-Obesity Pharmacotherapy (Class Effect), Lifestyle Counseling - Diet & Physical-Activity Program
Procedure · Drug · Behavioral
Lead sponsor
The Cleveland Clinic
Other
Eligibility
18 Years to 70 Years
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2034
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Dec 22, 2025 · Synced Sep 1, 2026, 1:46 PM EDT
Completed Phase 4 Interventional

Comparison of a Morphomic-Based to the Standard-of-Care-Based Cefazolin Dose for Antimicrobial Prophylaxis

NCT06005168
View directory record Official record
Conditions
Surgical Prophylaxis
Interventions
Cefazolin for Injection
Drug
Lead sponsor
University of Michigan
Other
Eligibility
18 Years and older
Enrollment
57 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Jan 29, 2026 · Synced Sep 1, 2026, 1:46 PM EDT
Completed Phase 2 Interventional Results available

Adjunct Phentermine + Topiramate After Bariatric Surgery in 12-24 Year Olds

NCT04095104
View directory record Official record
Conditions
Obesity, Morbid, Bariatric Surgery, Adolescent, Young Adult, Drug Therapy
Interventions
Phentermine, Immediate Release Topiramate, Placebo for Phentermine, Placebo for Immediate Release Topiramate
Drug
Lead sponsor
University of Colorado, Denver
Other
Eligibility
12 Years to 24 Years
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated May 22, 2025 · Synced Sep 1, 2026, 1:46 PM EDT
Terminated Phase 4 Interventional Results available

LOSS- Louisiana Obese Subjects Study

NCT00115063
View directory record Official record
Conditions
Obesity
Interventions
group sessions, sibutramine, orlistat, diethylpropion, Low Calorie Diet, Health One, Intensive Medical Combination Therapy for Obesity, Control Condition
Behavioral · Drug · Other
Lead sponsor
Pennington Biomedical Research Center
Other
Eligibility
20 Years to 60 Years
Enrollment
390 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2008
U.S. locations
1
States / cities
Baton Rouge, Louisiana
Source: ClinicalTrials.gov public record
Updated Feb 21, 2016 · Synced Sep 1, 2026, 1:46 PM EDT
Completed Not applicable Interventional

Point-of-Care Adipose-derived Cells for Hair Growth

NCT02729415
View directory record Official record
Conditions
Androgenetic Alopecia
Interventions
Stromal Vascular Fraction Cells (SVF Cells) Injection, Liposuction, Hair Measurements
Procedure · Other
Lead sponsor
University of Florida
Other
Eligibility
18 Years to 60 Years
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
1
States / cities
Gainesville, Florida
Source: ClinicalTrials.gov public record
Updated Mar 24, 2019 · Synced Sep 1, 2026, 1:46 PM EDT
Terminated Phase 4 Interventional Results available

Naltrexone/Bupropion Cardiovascular Outcomes Study

NCT02638129
View directory record Official record
Conditions
Obesity, Cardiovascular Diseases
Interventions
Naltrexone HCl/Bupropion HCl ER, Placebo
Drug
Lead sponsor
Orexigen Therapeutics, Inc
Industry
Eligibility
18 Years and older
Enrollment
67 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016
U.S. locations
139
States / cities
Alexander City, Alabama • Auburn, Alabama • Birmingham, Alabama + 136 more
Source: ClinicalTrials.gov public record
Updated Feb 26, 2017 · Synced Sep 1, 2026, 1:46 PM EDT
Recruiting Phase 2 Interventional Accepts healthy volunteers

Semaglutide for Post-Smoking Cessation Weight Management

NCT06173778
View directory record Official record
Conditions
Obesity, Overweight, Cigarette Smoking
Interventions
semaglutide 2.4mg, Placebo, Nicotine Replacement Therapy (NRT, nicotine patch), Brief Smoking Cessation Counseling
Drug · Behavioral
Lead sponsor
The University of Texas Health Science Center, Houston
Other
Eligibility
18 Years to 75 Years
Enrollment
197 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2026
U.S. locations
2
States / cities
Austin, Texas • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Feb 10, 2026 · Synced Sep 1, 2026, 1:46 PM EDT
Recruiting Phase 2 Interventional

HSCT for Patients With Fanconi Anemia Using Risk-Adjusted Chemotherapy

NCT02143830
View directory record Official record
Conditions
Fanconi Anemia, Severe Marrow Failure, Myelodysplastic Syndrome (MDS), Acute Myelogenous Leukemia (AML)
Interventions
Busulfan, Cyclophosphamide, Fludarabine, rabbit ATG, G-CSF, Peripheral blood stem cell
Drug · Biological
Lead sponsor
Children's Hospital Medical Center, Cincinnati
Other
Eligibility
3 Months and older
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2028
U.S. locations
3
States / cities
New York, New York • Cincinnati, Ohio • Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Nov 11, 2025 · Synced Sep 1, 2026, 1:46 PM EDT
Completed Phase 2 Interventional

Safety and Efficacy Study of 10XB-101 in Adults With Bilateral Flank Adiposity

NCT05760248
View directory record Official record
Conditions
Subcutaneous Fat Disorder
Interventions
10XB-101 Solution for Injection, 6.0%, Placebo Solution for Injection (no active ingredient)
Drug
Lead sponsor
10xBio, LLC
Industry
Eligibility
18 Years to 55 Years
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
2
States / cities
Rolling Meadows, Illinois • New Brighton, Minnesota
Source: ClinicalTrials.gov public record
Updated Jun 28, 2025 · Synced Sep 1, 2026, 1:46 PM EDT
Recruiting Phase 2 Interventional

MT2023-20: Hematopoietic Cell Transplant With Reduced Intensity Conditioning and Post-transplant Cyclophosphamide for Severe Aplastic Anemia and Other Forms of Acquired Bone Marrow Failure.

NCT06412497
View directory record Official record
Conditions
Severe Aplastic Anemia, Acquired Amegakaryocytic Thrombocytopenia, Acquired Pure Red Cell Aplasia, Paroxysmal Nocturnal Hemoglobinuria
Interventions
Rituximab, Rabbit ATG, Cyclophosphamide, Fludarabine, Total Body Irradiation, Cell Infusion, Post-Transplant G-CSF, Tacrolimus, Mycophenolate Mofetil
Drug · Radiation · Biological
Lead sponsor
Masonic Cancer Center, University of Minnesota
Other
Eligibility
0 Years to 75 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2036
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Jun 2, 2026 · Synced Sep 1, 2026, 1:46 PM EDT
Completed Phase 3 Interventional Results available

Individualized Obesity Pharmacotherapy

NCT03374956
View directory record Official record
Conditions
Obesity
Interventions
Phentermine-Topiramate, Liraglutide, Naltrexone/bupropion, Phentermine
Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years to 75 Years
Enrollment
193 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2022
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Jul 17, 2023 · Synced Sep 1, 2026, 1:46 PM EDT
Completed Early Phase 1 Interventional

A Novel Anti-Obesity Drug Combination as a Pharmacotherapy for Cocaine Dependence

NCT01739192
View directory record Official record
Conditions
Cocaine Use Disorders
Interventions
Bupropion
Drug
Lead sponsor
Craig Rush
Other
Eligibility
18 Years to 55 Years
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2018
U.S. locations
1
States / cities
Lexington, Kentucky
Source: ClinicalTrials.gov public record
Updated Jun 25, 2018 · Synced Sep 1, 2026, 1:46 PM EDT
Completed Phase 2 Interventional

Allo HSCT Using RIC for Hematological Diseases

NCT02661035
View directory record Official record
Conditions
Acute Myelogenous Leukemia, Acute Lymphocytic Leukemia, Chronic Myelogenous Leukemia, Plasma Cell Leukemia, Myelodysplastic Syndromes, Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, B-Cell Lymphoma, Follicular Lymphoma, Lymphoplasmacytic Lymphoma, Mantle-Cell Lymphoma, Prolymphocytic Leukemia, Lymphoblastic Lymphoma, Burkitt's Lymphoma, Non-Hodgkin's Lymphoma, Multiple Myeloma, Myeloproliferative Syndromes, Hematological Diseases
Interventions
Allopurinol, Fludarabine, Cyclophosphamide, ATG, TBI, Tacrolimus, MMF, Peripheral Blood Stem Cells, Related or Unrelated Bone Marrow Cells
Drug · Radiation · Biological
Lead sponsor
Masonic Cancer Center, University of Minnesota
Other
Eligibility
Up to 75 Years
Enrollment
156 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2023
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Sep 20, 2023 · Synced Sep 1, 2026, 1:46 PM EDT